1239441-36-1 Usage
General Description
6-Bromo-3-chloro-imidazo[1,2-a]pyrazine is a heterocyclic organic compound with a fused imidazole-pyrazine ring system. It is a derivative of imidazo[1,2-a]pyrazine and contains both bromine and chlorine as substituents on the heterocyclic ring. 6-Bromo-3-chloro-imidazo[1,2-a]pyrazine has potential applications in medicinal chemistry and agrochemical industries due to its biological activity and reactivity. It can be used as a building block in the synthesis of various pharmaceuticals and agrochemicals. Additionally, it may have potential as a ligand in coordination chemistry for the design of new metal complexes. Its unique structural features make it a valuable intermediate for the synthesis of complex organic molecules.
Check Digit Verification of cas no
The CAS Registry Mumber 1239441-36-1 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,2,3,9,4,4 and 1 respectively; the second part has 2 digits, 3 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 1239441-36:
(9*1)+(8*2)+(7*3)+(6*9)+(5*4)+(4*4)+(3*1)+(2*3)+(1*6)=151
151 % 10 = 1
So 1239441-36-1 is a valid CAS Registry Number.
1239441-36-1Relevant articles and documents
SMALL MOLECULE INHIBITORS OF DYRK/CLK AND USES THEREOF
-
Paragraph 0580-0581, (2020/02/19)
This invention is in the field of medicinal chemistry. In particular, the invention relates to a new class of small-molecules having a 6,5-heterocyclic structure (e.g., compounds having a imidazopyridine, imidazopyrimidine, imidazopyrazine, imidazopyridazine, imidazotriazine, benzoimidazole, benzotriazole, benzoisoxazole, purine, indazole, triazolotriazine, triazolopyridazine, triazolopyrimidine, triazolopyrazine, triazolotetrazine, triazolopyridine, pyrazolopyrazine, pyrazolopyrimidine, pyrazolopyridazine, pyrazolotriazine, pyrazolopyridine, isoxazolopyrazine, isoxazolopyrimidine, isoxazolopyrdiazine, isoxazolotriazine, or isoxalopyridine structure) which function as inhibitors of DYRK1A, DYRK1B, and Clk-1, and their use as therapeutics for the treatment of Alzheimer's disease, Down syndrome, diabetes, glioblastoma, autoimmune diseases, cancer (e.g., glioblastoma, prostate cancer), inflammatory disorders (e.g., airway inflammation), and other diseases.
